Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Ahead of key panel vote, FDA staff raises concerns over Novo diabetes drug
Ahead of key panel vote, FDA staff raises concerns over Novo diabetes drug
Ahead of key panel vote, FDA staff raises concerns over Novo diabetes drug
Submitted by
admin
on May 23, 2016 - 10:40am
Source:
BioPharma Dive
News Tags:
FDA
advisory panels
Novo Nordisk
diabetes
IDegLira
Headline:
Ahead of key panel vote, FDA staff raises concerns over Novo diabetes drug
Do Not Allow Advertisers to Use My Personal information
